ArticleBMJ open2026
Seroprevalence of Japanese encephalitis virus and other flavivirus-specific antibodies among Australian blood donors following a novel epidemic spread of Japanese encephalitis virus: a cross-sectional study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn 2022, Japanese encephalitis virus (JEV) was detected in humans and animals across mainland Australia. We examined the prevalence of JEV and endemic flaviviruses, Murray Valley encephalitis virus (MVEV) and Kunjin virus (KUNV) antibodies in blood donors in different risk geographic areas across southern Australia.
designProspective cross-sectional serosurvey for JEV, MVEV and KUNV-specific antibodies.
settingSouthern Australia.
participantsAll Australian blood donors who attended nine high-risk (geographical proximity to recent human, animal and/or vector detections of JEV) and three low-risk (no competent JEV vector and no animal or human detections were nearby) donor centres between 8-26 August or 12-17 September 2022 were analysed. PRIMARY AND SECONDARY OUTCOME MEASURES: Seroprevalence estimates of JEV, MVEV and KUNV-specific antibodies were compared between blood donors from collection sites in areas considered high-risk and low-risk for JEV infection. Seroprevalence estimates were adjusted for age and sex after excluding donors born in JEV-endemic countries and those with documented JEV vaccination.
resultsJEV-specific antibody seroprevalence was 1.6% (95% CI 1.3% to 2.0%) from 5257 samples. Odds of JEV seropositivity were greater in high-risk versus low-risk areas (OR 1.8, 95% CI 1.5 to 2.2; absolute risk difference: 0.8 percentage points) and in males versus females (OR 2.1, 95% CI 1.2 to 3.6). In high-risk areas, people ≥70 years had higher seroprevalences than those aged 18-29 (OR 3.1, 95% CI 1.8 to 5.5). MVEV and KUNV-specific antibody seroprevalence were 2.2% (95% CI 1.9% to 2.7%) and 3.7% (95% CI 3.2% to 4.3%), respectively, with higher prevalence in high-risk areas (MVEV OR 2.6, 95% CI 1.6 to 4.3; KUNV OR 2.4, 95% CI 1.9 to 3.0) and older ages.
conclusionsBlood donors in areas where JEV emerged in the 2021-2022 Australian summer had a 0.8 percentage point higher seroprevalence compared with non-JEV transmission areas, with older male donors most likely to be seropositive. Patterns were similar for endemic flaviviruses. This data informed recommendations for JEV vaccine distribution to high-risk areas and the need for non-pharmaceutical mosquito prevention strategies across Australia, given the highly susceptible population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.